Fred Hutch researcher zeroes in on biomarkers to better predict aggressive form of the disease
Sept. 4, 2018
| By Diane Mapes / Fred Hutch News Service
Prostate cancers are not all the same. Some are extremely aggressive: They can and do kill. Others are slow-growing and don’t kill: Men die with them, not of them. How can doctors and patients discern which one is which? Fred Hutch's Dr. Janet Stanford believes she may have found a way.
Researchers show how common mutation in SCLC makes mouse tumors more vulnerable to certain cancer drugs
Sept. 4, 2018
| By Sabrina Richards / Fred Hutch News Service
Work by Dr. David MacPherson could point the way toward a targeted treatment for a subset of small-cell lung cancers. He showed that SCLC tumors with a specific DNA mutation are more vulnerable to certain drugs.
Biostatistician plans to use funds to develop statistical models to further precision cancer prevention and treatment
Aug. 20, 2018
| By Colin Petersdorf / Fred Hutch News Service
Fred Hutch biostatistician Dr. James Dai recently was awarded a $2.1 million grant from the National Cancer Institute to develop new analytical methods for identifying genetic and epigenetic alterations that drive cancers. He hopes this work will facilitate the discovery of molecular cancer drivers — biomarkers — and the development of new preventive, diagnostic and prognostic techniques.
Fred Hutch is proud to be an Equal Opportunity and VEVRAA Employer. We are committed to cultivating a workplace in which diverse perspectives and experiences are welcomed and respected. We do not discriminate on the basis of race, color, religion, creed, ancestry, national origin, sex, age, disability, marital or veteran status, sexual orientation, gender identity, political ideology, or membership in any other legally protected class. We are an Affirmative Action employer. We encourage individuals with diverse backgrounds to apply and desire priority referrals of protected veterans. Read the EEO is the Law poster here.